Nūhou
Hāʻawi ka lāʻau lapaʻau CD19/BCMA CAR-T pālua a BIOOCUS Medical Group i nā hopena hoʻohiki i ka Myasthenia Gravis Refractory: He huakaʻi a kahi maʻi ʻōpio
Ua hoʻokō ka mea maʻi ʻAukekulelia i ka pane mua kupaianaha me ka lāʻau lapaʻau Dual CD19/CD20 CAR-T a BIOOCUS Medical Group no ka DLBCL i hoʻihoʻi ʻia
Ke Koʻikoʻi o ka Hahai Mau ʻana a me nā Nānā Ma hope o ka Hoʻoili ʻana o nā Kelepona Kumu Hematopoietic
He mea koʻikoʻi ka hahai ʻana ma hope o ke kāpili ʻana no nā poʻe maʻi hoʻoili cell kumu hematopoietic (HSCT). Kōkua nā nānā mau ʻana i ka ʻike ʻana i nā pilikia e like me nā maʻi, ka maʻi graft-versus-host (GVHD), a me ka hoʻi hou ʻana, e hōʻoia ana i ke komo mua ʻana a me nā hopena maikaʻi aʻe.
Ua lanakila ka CAR-T Therapy i ka Prognosis maikaʻi ʻole ma ka Lymphoma B-Cell kiʻekiʻe
Ua hōʻike ʻia kahi noiʻi hou e hiki i ka lāʻau lapaʻau CAR-T ke hoʻomaikaʻi i ka prognosis no nā poʻe maʻi me ka lymphoma B-cell kiʻekiʻe (HGBL), kahi ʻano o ka lymphoma B-cell nui, ʻoiai ma nā laina lapaʻau ma hope, e hāʻawi ana i ka manaʻolana hou no kēia mau hihia paʻakikī.
ʻO ke komo mua ʻana me ka CAR-T Therapy no ka Lymphoma B-Cell Nui e hōʻike ana i nā hopena hoʻohiki
Ua hōʻike ʻia kahi noiʻi i hala i ka wā e hoʻohālikelike ana i ka lāʻau CAR-T mua a me ka lāʻau CAR-T hope i nā poʻe maʻi lymphoma B-cell nui e hiki i ka lāʻau mua ke hāʻawi i nā helu ola i hoʻomaikaʻi ʻia a me nā hopena ʻaoʻao liʻiliʻi, e kākoʻo ana i kona hoʻohana ʻana ma ke ʻano he lāʻau lapaʻau laina lua.
Hōʻike ka CAR-T Therapy i ka palekana a me ka pono i nā poʻe maʻi kanesa me nā maʻi Autoimmune a i ʻole Inflammatory
Ua paʻi ʻia kahi noiʻi hou i loko o ʻO ka Lancet Rheumatology hōʻike i ka palekana a me ka pono o ka CAR-T cell therapy no ka mālama ʻana i ka lymphoma a me nā maʻi myeloma he nui i loaʻa i nā maʻi autoimmune a i ʻole nā maʻi mumū, e hāʻawi ana i nā hōʻike hoʻohiki no kāna noi ākea.
Nā ʻIke Hou i nā ʻAno Genetic o ka B-ALL makua
He loiloi piha ma Koko hōʻike i nā holomua hou i ka hoʻomaopopo ʻana i nā ʻano genetic o ka maʻi B-cell Acute Lymphoblastic Leukemia (B-ALL) makua. Ke noiʻi nei ke aʻo ʻana i ka heterogeneity biological, nā hopena lapaʻau, a me ke koʻikoʻi o ka lāʻau lapaʻau pololei i ka hoʻomaikaʻi ʻana i nā hopena o ka mea maʻi.
Ua hōʻoia ka Haʻawina Hou i ka Palekana a me ka Pono o ka CD19/CD20 CAR-T Therapy no r/r B-NHL
Ua hōʻike ʻia kahi hoʻokolohua multicenter pae 1 ma Kina i ka palekana a me ka pono o ka prizlon-cel, kahi lāʻau lapaʻau CD19/CD20 CAR-T pālua-i hoʻolālā ʻia, e hāʻawi ana i ka manaʻolana hou no nā poʻe maʻi me ka lymphoma B-cell non-Hodgkin relapsed/refractory (r/r B-NHL).
Ua wānana nā Biomarkers Hou i nā hopena CAR-T Therapy i ka mālama ʻana i ka Multiple Myeloma
Ua paʻi ʻia kahi noiʻi hou i loko o Koko ʻike i nā pae BCMA soluble (sBCMA) a me ka nui o ka tumor metabolic (MTV) ma ke ʻano he biomarkers hiki ke wānana i nā hopena therapy CAR-T i nā maʻi myeloma multiple relapsed a me refractory (RRMM), e hoʻomākaukau ana i ke ala no nā hoʻolālā lapaʻau pilikino.
ʻO ka lāʻau lapaʻau CAR-T: He wā e hiki mai ana no nā maʻi ʻino T-Cell
ʻO ka lāʻau lapaʻau CAR-T, kahi holomua mua no nā maʻi ʻino B-cell, ke hōʻike nei i ka manaʻolana i ka mālama ʻana i nā lymphomas T-cell a me ka T-cell acute lymphoblastic leukemia (T-ALL). Ke kū nei kēia lāʻau lapaʻau e ulu nei i nā pilikia kūikawā akā hāʻawi nā hoʻokolohua lapaʻau hou i ka manaʻolana no nā hopena therapeutic hou i nā maʻi ʻino T-cell.
Haʻawina Hoʻolaha i Paʻi ʻia ma ke Koko: Nanobody-Based CD7 CAR-T Therapy no ka Acute Myeloid Leukemia
Ua hoʻokō ka Lu Daopei Medical Team i kahi holomua koʻikoʻi i ka mālama ʻana i ka Acute Myeloid Leukemia (AML) me kā lākou noiʻi ʻana i ka lāʻau lapaʻau CD7 CAR-T i hoʻokumu ʻia ma ka nanobody, i paʻi ʻia ma ka puke pai hanohano. Koko.
Nā mea hoʻopale Menin: He lāʻau lapaʻau hou no ka maʻi leukemia myeloid koʻikoʻi
Hāʻawi nā holomua hou i nā mea hoʻopaʻa Menin i nā koho lapaʻau hoʻohiki no ka leukemia myeloid acute (AML), e kālele ana i nā hoʻololi genetic a hāʻawi i ka manaʻolana hou no nā hihia paʻakikī.